Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$1.93 /

-0.33 (-14.63%)

08:14
03/13/20
03/13
08:14
03/13/20
08:14

Lexicon announces additional data on XERMELO effects in carcinoid syndrome

Lexicon Pharmaceuticals announced additional data on XERMELO's antiproliferative effects in patients with carcinoid syndrome that were presented at the European Neuroendocrine Tumor Society meeting. XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use. Data from a retrospective, pre- and post-design chart review of 200 metastatic neuroendocrine tumor patients who were on standard background therapies and received telotristat ethyl for an average of 12 months in US clinical practice demonstrated that most patients had no tumor progression at 6, 12 and 18 months following initiation of telotristat ethyl, with a median time to tumor progression of 39.8 months. The majority of patients also experienced progression-free survival in the post-telotristat ethyl period, with a median PFS of 23.7 months. In addition, in a subset of 22 patients with recorded biomarker data, mean serotonin levels decreased significantly in the post-telotristat ethyl period. Patients also improved on carcinoid syndrome symptoms, body weight and performance status.

LXRX Lexicon
$1.93 /

-0.33 (-14.63%)

12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
11/08/19 Citi
Lexicon downgraded to Neutral from Buy at Citi

TODAY'S FREE FLY STORIES

Earnings
ContraFect reports Q2 EPS (88c), consensus (37c) » 07:33
08/14/20
08/14
07:33
08/14/20
07:33
CFRX

ContraFect

$5.16 /

-0.24 (-4.44%)

"We continued to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

06/09/20
Fly Intel: Top five analyst initiations
06/09/20 Mizuho
ContraFect initiated with a Buy at Mizuho
06/08/20 Cantor Fitzgerald
ContraFect initiated with an Overweight at Cantor Fitzgerald
10/02/19 Piper Jaffray
Piper says design differentiates ContraFect trial from other antibiotic studies
CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

  • 22
    May
  • 10
    Dec
CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

CFRX ContraFect
$5.16 /

-0.24 (-4.44%)

Recommendations
Farfetch price target raised to $31 from $20.50 at BTIG » 07:33
08/14/20
08/14
07:33
08/14/20
07:33
FTCH

Farfetch

$26.38 /

+0.45 (+1.74%)

BTIG analyst Marvin Fong…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FTCH Farfetch
$26.38 /

+0.45 (+1.74%)

FTCH Farfetch
$26.38 /

+0.45 (+1.74%)

08/11/20 Credit Suisse
Farfetch price target raised to $29 from $20 at Credit Suisse
07/14/20 Oppenheimer
Farfetch price target raised to $23 from $16 at Oppenheimer
07/08/20 China Renaissance
Farfetch upgraded to Buy from Hold at China Renaissance
07/01/20 Deutsche Bank
Farfetch price target raised to $23 from $17 at Deutsche Bank
FTCH Farfetch
$26.38 /

+0.45 (+1.74%)

FTCH Farfetch
$26.38 /

+0.45 (+1.74%)

FTCH Farfetch
$26.38 /

+0.45 (+1.74%)

Recommendations
SharpSpring price target raised to $15 from $12 at Roth Capital » 07:32
08/14/20
08/14
07:32
08/14/20
07:32
SHSP

SharpSpring

$9.27 /

+0.26 (+2.89%)

Roth Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SHSP SharpSpring
$9.27 /

+0.26 (+2.89%)

SHSP SharpSpring
$9.27 /

+0.26 (+2.89%)

07/22/20 Roth Capital
SharpSpring price target lowered to $12 from $14 at Roth Capital
04/15/20 Craig-Hallum
SharpSpring assumed with a Buy at Craig-Hallum
03/13/20 Lake Street
SharpSpring price target lowered to $14 from $17 at Lake Street
SHSP SharpSpring
$9.27 /

+0.26 (+2.89%)

SHSP SharpSpring
$9.27 /

+0.26 (+2.89%)

Recommendations
AMC Networks price target lowered to $27 from $31 at Guggenheim » 07:32
08/14/20
08/14
07:32
08/14/20
07:32
AMCX

AMC Networks

$24.88 /

-0.135 (-0.54%)

Guggenheim analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMCX AMC Networks
$24.88 /

-0.135 (-0.54%)

AMCX AMC Networks
$24.88 /

-0.135 (-0.54%)

08/07/20 Macquarie
AMC Networks upgraded to Outperform from Neutral at Macquarie
07/13/20
Fly Intel: Top five analyst initiations
07/13/20 Goldman Sachs
AMC Networks initiated with a Sell at Goldman Sachs
06/19/20 Macquarie
AMC Networks price target raised to $29 from $26 at Macquarie
AMCX AMC Networks
$24.88 /

-0.135 (-0.54%)

AMCX AMC Networks
$24.88 /

-0.135 (-0.54%)

AMCX AMC Networks
$24.88 /

-0.135 (-0.54%)

Earnings
Lithium Americas reports Q2 EPS (7c) vs. (7c) last year » 07:30
08/14/20
08/14
07:30
08/14/20
07:30
LAC

Lithium Americas

$7.35 /

+0.225 (+3.16%)

"We remain focused…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LAC Lithium Americas
$7.35 /

+0.225 (+3.16%)

LAC Lithium Americas
$7.35 /

+0.225 (+3.16%)

06/25/20 BMO Capital
Lithium Americas price target raised to C$5 from C$4.40 at BMO Capital
LAC Lithium Americas
$7.35 /

+0.225 (+3.16%)

Upgrade
MSG Networks upgraded to Neutral from Sell at Guggenheim » 07:30
08/14/20
08/14
07:30
08/14/20
07:30
MSGN

MSG Networks

$10.67 /

+0.06 (+0.57%)

Guggenheim analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MSGN MSG Networks
$10.67 /

+0.06 (+0.57%)

06:22 Today Guggenheim
MSG Networks upgraded to Neutral from Sell at Guggenheim
06/25/20 Wolfe Research
MSG Networks initiated with an Underperform at Wolfe Research
06/09/20 Imperial Capital
MSG Networks price target raised to $13 from $12 at Imperial Capital
05/04/20 Guggenheim
MSG Networks price target lowered to $10 from $13 at Guggenheim
MSGN MSG Networks
$10.67 /

+0.06 (+0.57%)

Recommendations
BioMarin price target raised to $218 from $172 at Goldman Sachs » 07:29
08/14/20
08/14
07:29
08/14/20
07:29
BMRN

BioMarin

$116.75 /

-1.24 (-1.05%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BMRN BioMarin
$116.75 /

-1.24 (-1.05%)

BMRN BioMarin
$116.75 /

-1.24 (-1.05%)

08/05/20 SVB Leerink
BioMarin price target raised to $140 from $130 at SVB Leerink
08/05/20 Barclays
BioMarin price target raised to $135 from $125 at Barclays
08/05/20 JPMorgan
BioMarin price target raised to $156 from $140 at JPMorgan
08/05/20 Cantor Fitzgerald
BioMarin shares can re-rate further despite 42% rally, says Cantor Fitzgerald
BMRN BioMarin
$116.75 /

-1.24 (-1.05%)

BMRN BioMarin
$116.75 /

-1.24 (-1.05%)

BMRN BioMarin
$116.75 /

-1.24 (-1.05%)

Recommendations
Disney price target raised to $136 from $120 at Wells Fargo » 07:28
08/14/20
08/14
07:28
08/14/20
07:28
DIS

Disney

$130.93 /

-0.81 (-0.61%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DIS Disney
$130.93 /

-0.81 (-0.61%)

DIS Disney
$130.93 /

-0.81 (-0.61%)

08/05/20
Fly Intel: Top five analyst upgrades
08/05/20 JPMorgan
Disney remains top pick in media post Q3 results at JPMorgan
08/05/20 Needham
Needham says still 'too early' to buy Disney, keeps Hold rating after earnings
08/05/20 BMO Capital
Disney price target raised to $150 from $140 at BMO Capital
DIS Disney
$130.93 /

-0.81 (-0.61%)

DIS Disney
$130.93 /

-0.81 (-0.61%)

DIS Disney
$130.93 /

-0.81 (-0.61%)

DIS Disney
$130.93 /

-0.81 (-0.61%)

Initiation
NMI Holdings initiated with a Buy at Citi » 07:22
08/14/20
08/14
07:22
08/14/20
07:22
NMIH

NMI Holdings

/

+

Citi analyst Arren…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NMIH NMI Holdings
/

+

NMIH NMI Holdings
/

+

06:39 Today Citi
NMI Holdings initiated with a Buy at Citi
07/20/20 Susquehanna
NMI Holdings consensus loss ratio estimates too high. says Susquehanna
07/15/20 JPMorgan
NMI upgraded to Overweight on capital position at JPMorgan
07/15/20 JPMorgan
NMI Holdings upgraded to Overweight from Neutral at JPMorgan
NMIH NMI Holdings
/

+

  • 04
    Jun
NMIH NMI Holdings
/

+

NMIH NMI Holdings
/

+

Downgrade
New Relic downgraded to Hold from Buy at Argus » 07:22
08/14/20
08/14
07:22
08/14/20
07:22
NEWR

New Relic

$55.78 /

+1.25 (+2.29%)

Argus analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NEWR New Relic
$55.78 /

+1.25 (+2.29%)

NEWR New Relic
$55.78 /

+1.25 (+2.29%)

07:13 Today Argus
New Relic downgraded to Hold from Buy at Argus
08/05/20 UBS
New Relic sales turnaround taking longer than expected, says UBS
08/05/20 JPMorgan
New Relic downgraded to Neutral on strategy change at JPMorgan
08/05/20 JPMorgan
New Relic downgraded to Neutral from Overweight at JPMorgan
NEWR New Relic
$55.78 /

+1.25 (+2.29%)

NEWR New Relic
$55.78 /

+1.25 (+2.29%)

Recommendations
Wells Fargo prefers Target to Walmart ahead of earnings next week » 07:21
08/14/20
08/14
07:21
08/14/20
07:21
TGT

Target

$134.82 /

+0.21 (+0.16%)

, WMT

Walmart

$131.83 /

+1.04 (+0.80%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TGT Target
$134.82 /

+0.21 (+0.16%)

WMT Walmart
$131.83 /

+1.04 (+0.80%)

TGT Target
$134.82 /

+0.21 (+0.16%)

06:46 Today DA Davidson
Target initiated with a Buy at DA Davidson
08/13/20 Baird
Target price target raised to $150 from $135 at Baird
08/12/20 JPMorgan
JPMorgan adds Target to Analyst Focus List, raises price target to $154
08/11/20 Morgan Stanley
Target price target raised to $135 from $120 at Morgan Stanley
WMT Walmart
$131.83 /

+1.04 (+0.80%)

06:46 Today DA Davidson
Walmart initiated with a Buy at DA Davidson
07/30/20
Fly Intel: Top five analyst initiations
07/30/20 MKM Partners
BJ's Wholesale initiated with a Sell at MKM Partners
07/30/20 MKM Partners
Target initiated with a Sell at MKM Partners
TGT Target
$134.82 /

+0.21 (+0.16%)

WMT Walmart
$131.83 /

+1.04 (+0.80%)

TGT Target
$134.82 /

+0.21 (+0.16%)

WMT Walmart
$131.83 /

+1.04 (+0.80%)

TGT Target
$134.82 /

+0.21 (+0.16%)

WMT Walmart
$131.83 /

+1.04 (+0.80%)

TGT Target
$134.82 /

+0.21 (+0.16%)

WMT Walmart
$131.83 /

+1.04 (+0.80%)

Initiation
NetEase initiated with a Buy at Daiwa » 07:18
08/14/20
08/14
07:18
08/14/20
07:18
NTES

NetEase

$464.95 /

-9.21 (-1.94%)

Daiwa analyst John Choi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NTES NetEase
$464.95 /

-9.21 (-1.94%)

NTES NetEase
$464.95 /

-9.21 (-1.94%)

07:13 Today Benchmark
NetEase price target raised to $520 from $435 at Benchmark
07/27/20 Barclays
NetEase price target raised to $500 from $450 at Barclays
07/21/20 Citi
NetEase price target raised to $543 from $453 at Citi
06/12/20
Fly Intel: Top five analyst initiations
NTES NetEase
$464.95 /

-9.21 (-1.94%)

NTES NetEase
$464.95 /

-9.21 (-1.94%)

NTES NetEase
$464.95 /

-9.21 (-1.94%)

NTES NetEase
$464.95 /

-9.21 (-1.94%)

Earnings
Bio-Path Holdings reports Q2 EPS (55c), one est. (96c) » 07:18
08/14/20
08/14
07:18
08/14/20
07:18
BPTH

Bio-Path Holdings

$5.53 /

+0.79 (+16.67%)

"Despite the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BPTH Bio-Path Holdings
$5.53 /

+0.79 (+16.67%)

BPTH Bio-Path Holdings
$5.53 /

+0.79 (+16.67%)

05/18/20 H.C. Wainwright
Bio-Path Holdings price target lowered to $18 from $25 at H.C. Wainwright
BPTH Bio-Path Holdings
$5.53 /

+0.79 (+16.67%)

Hot Stocks
Apollo Infrastructure Funds announces strategic investment in US Wind » 07:16
08/14/20
08/14
07:16
08/14/20
07:16
APO

Apollo Global

$48.45 /

+0.37 (+0.77%)

Apollo Global Management…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APO Apollo Global
$48.45 /

+0.37 (+0.77%)

APO Apollo Global
$48.45 /

+0.37 (+0.77%)

07/01/20 Barclays
Apollo Global price target raised to $51 from $44 at Barclays
06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 Goldman Sachs
Apollo Global downgraded to Buy from Conviction Buy at Goldman Sachs
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
APO Apollo Global
$48.45 /

+0.37 (+0.77%)

  • 26
    Nov
APO Apollo Global
$48.45 /

+0.37 (+0.77%)

APO Apollo Global
$48.45 /

+0.37 (+0.77%)

APO Apollo Global
$48.45 /

+0.37 (+0.77%)

Downgrade
Meredith downgraded to Hold from Buy at Benchmark » 07:16
08/14/20
08/14
07:16
08/14/20
07:16
MDP

Meredith

$16.06 /

+0.175 (+1.10%)

Benchmark analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MDP Meredith
$16.06 /

+0.175 (+1.10%)

MDP Meredith
$16.06 /

+0.175 (+1.10%)

06:19 Today Benchmark
Meredith downgraded to Hold from Buy at Benchmark
06/29/20 Citi
Meredith price target lowered to $18 from $20 at Citi
06/04/20 Citi
Meredith price target raised to $20 from $16 at Citi
03/06/20 Benchmark
Meredith dividend looks 'very safe,' says Benchmark
MDP Meredith
$16.06 /

+0.175 (+1.10%)

MDP Meredith
$16.06 /

+0.175 (+1.10%)

MDP Meredith
$16.06 /

+0.175 (+1.10%)

Initiation
Sea Limited initiated with an Add at CIMB » 07:15
08/14/20
08/14
07:15
08/14/20
07:15
SE

Sea Limited

$127.95 /

+1.15 (+0.91%)

CIMB analyst Ngoh Yi Sin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SE Sea Limited
$127.95 /

+1.15 (+0.91%)

SE Sea Limited
$127.95 /

+1.15 (+0.91%)

08/13/20 Macquarie
Sea Limited initiated with an Underperform at Macquarie
07/08/20 Citi
Sea Limited price target raised to $138 from $79 at Citi
06/30/20 Stephens
Sea Limited initiated with an Overweight at Stephens
06/30/20 Stephens
Sea Limited initiated with an Overweight at Stephens
SE Sea Limited
$127.95 /

+1.15 (+0.91%)

SE Sea Limited
$127.95 /

+1.15 (+0.91%)

SE Sea Limited
$127.95 /

+1.15 (+0.91%)

Recommendations
FedEx price target raised to $221 from $179 at Wells Fargo » 07:15
08/14/20
08/14
07:15
08/14/20
07:15
FDX

FedEx

$203.88 /

+2.06 (+1.02%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FDX FedEx
$203.88 /

+2.06 (+1.02%)

FDX FedEx
$203.88 /

+2.06 (+1.02%)

08/13/20 Citi
FedEx still has 'meaningful upside,' says Citi
08/12/20 UBS
FedEx price target raised to $218 from $181 at UBS
08/10/20
Fly Intel: Top five analyst upgrades
08/10/20 Bernstein
FedEx upgraded to Outperform from at Bernstein
FDX FedEx
$203.88 /

+2.06 (+1.02%)

FDX FedEx
$203.88 /

+2.06 (+1.02%)

FDX FedEx
$203.88 /

+2.06 (+1.02%)

FDX FedEx
$203.88 /

+2.06 (+1.02%)

Downgrade
Vroom downgraded to Hold from Buy at Benchmark on revenue reset » 07:14
08/14/20
08/14
07:14
08/14/20
07:14
VRM

Vroom

$56.34 /

-13 (-18.75%)

Benchmark analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRM Vroom
$56.34 /

-13 (-18.75%)

VRM Vroom
$56.34 /

-13 (-18.75%)

06:20 Today Benchmark
Vroom downgraded to Hold from Buy at Benchmark
08/13/20 Wells Fargo
Vroom price target raised to $76 from $65 at Wells Fargo
08/13/20 Wedbush
Vroom price target raised to $80 from $75 at Wedbush
08/13/20 Baird
Baird would be buyers of Vroom amid post-earnings weakness
VRM Vroom
$56.34 /

-13 (-18.75%)

  • 09
    Jun
VRM Vroom
$56.34 /

-13 (-18.75%)

VRM Vroom
$56.34 /

-13 (-18.75%)

Hot Stocks
SCWorx appoints Timothy Hannibal as president, COO » 07:14
08/14/20
08/14
07:14
08/14/20
07:14
WORX

SCWorx

$2.33 /

+0.27 (+13.11%)

SCWorx announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WORX SCWorx
$2.33 /

+0.27 (+13.11%)

WORX SCWorx
$2.33 /

+0.27 (+13.11%)

WORX SCWorx
$2.33 /

+0.27 (+13.11%)

Recommendations
NetEase price target raised to $520 from $435 at Benchmark » 07:13
08/14/20
08/14
07:13
08/14/20
07:13
NTES

NetEase

$464.95 /

-9.21 (-1.94%)

Benchmark analyst Fawne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NTES NetEase
$464.95 /

-9.21 (-1.94%)

NTES NetEase
$464.95 /

-9.21 (-1.94%)

07/27/20 Barclays
NetEase price target raised to $500 from $450 at Barclays
07/21/20 Citi
NetEase price target raised to $543 from $453 at Citi
06/12/20
Fly Intel: Top five analyst initiations
06/11/20 Goldman Sachs
NetEase initiated with a Buy at Goldman Sachs
NTES NetEase
$464.95 /

-9.21 (-1.94%)

NTES NetEase
$464.95 /

-9.21 (-1.94%)

NTES NetEase
$464.95 /

-9.21 (-1.94%)

NTES NetEase
$464.95 /

-9.21 (-1.94%)

Downgrade
New Relic downgraded to Hold from Buy at Argus » 07:13
08/14/20
08/14
07:13
08/14/20
07:13
NEWR

New Relic

$55.78 /

+1.25 (+2.29%)

Argus analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NEWR New Relic
$55.78 /

+1.25 (+2.29%)

NEWR New Relic
$55.78 /

+1.25 (+2.29%)

08/05/20 UBS
New Relic sales turnaround taking longer than expected, says UBS
08/05/20 JPMorgan
New Relic downgraded to Neutral on strategy change at JPMorgan
08/05/20 JPMorgan
New Relic downgraded to Neutral from Overweight at JPMorgan
08/04/20 BMO Capital
New Relic price target raised to $78 from $70 at BMO Capital
NEWR New Relic
$55.78 /

+1.25 (+2.29%)

NEWR New Relic
$55.78 /

+1.25 (+2.29%)

Hot Stocks
BioXcel Therapeutics sees cash runway well into 2022 » 07:12
08/14/20
08/14
07:12
08/14/20
07:12
BTAI

BioXcel Therapeutics

$44.71 /

+0.45 (+1.02%)

In July 2020, the Company…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

07/21/20 Canaccord
BioXcel Therapeutics price target raised to $120 from $71 at Canaccord
07/20/20 BMO Capital
BioXcel Therapeutics price target raised to $104 from $64 at BMO Capital
07/20/20 H.C. Wainwright
BioXcel Therapeutics price target raised to $200 from $120 at H.C. Wainwright
07/08/20 H.C. Wainwright
BioXcel Therapeutics price target raised to $120 from $95 at H.C. Wainwright
BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

  • 29
    Jul
  • 20
    Feb
  • 26
    Sep
BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

Upgrade
Tapestry upgraded to Outperform from In Line at Evercore ISI » 07:12
08/14/20
08/14
07:12
08/14/20
07:12
TPR

Tapestry

$15.42 /

-0.15 (-0.96%)

Evercore ISI analyst Omar…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TPR Tapestry
$15.42 /

-0.15 (-0.96%)

TPR Tapestry
$15.42 /

-0.15 (-0.96%)

07/27/20
Fly Intel: Top five analyst upgrades
07/27/20 Goldman Sachs
Tapestry upgraded to Buy from Neutral at Goldman Sachs
05/07/20
Fly Intel: Top five analyst upgrades
05/07/20 HSBC
Tapestry upgraded to Buy from Hold at HSBC
TPR Tapestry
$15.42 /

-0.15 (-0.96%)

TPR Tapestry
$15.42 /

-0.15 (-0.96%)

TPR Tapestry
$15.42 /

-0.15 (-0.96%)

TPR Tapestry
$15.42 /

-0.15 (-0.96%)

Hot Stocks
BioXcel expects data from Phase 1b/2 study of BXCL701 later this year » 07:12
08/14/20
08/14
07:12
08/14/20
07:12
BTAI

BioXcel Therapeutics

$44.71 /

+0.45 (+1.02%)

The Phase 2 portion of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

07/21/20 Canaccord
BioXcel Therapeutics price target raised to $120 from $71 at Canaccord
07/20/20 BMO Capital
BioXcel Therapeutics price target raised to $104 from $64 at BMO Capital
07/20/20 H.C. Wainwright
BioXcel Therapeutics price target raised to $200 from $120 at H.C. Wainwright
07/08/20 H.C. Wainwright
BioXcel Therapeutics price target raised to $120 from $95 at H.C. Wainwright
BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

  • 29
    Jul
  • 20
    Feb
  • 26
    Sep
BTAI BioXcel Therapeutics
$44.71 /

+0.45 (+1.02%)

Upgrade
Qiagen upgraded to Outperform from Neutral at Exane BNP Paribas » 07:11
08/14/20
08/14
07:11
08/14/20
07:11
QGEN

Qiagen

$48.66 /

+0.24 (+0.50%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
QGEN Qiagen
$48.66 /

+0.24 (+0.50%)

QGEN Qiagen
$48.66 /

+0.24 (+0.50%)

03/04/20 Stifel
Qiagen deal a positive for Thermo Fisher, says Stifel
03/04/20 Berenberg
Qiagen downgraded to Hold from Buy at Berenberg
03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/05/20 Piper Sandler
Qiagen price target raised to $36 from $29 at Piper Sandler
QGEN Qiagen
$48.66 /

+0.24 (+0.50%)

QGEN Qiagen
$48.66 /

+0.24 (+0.50%)

QGEN Qiagen
$48.66 /

+0.24 (+0.50%)

QGEN Qiagen
$48.66 /

+0.24 (+0.50%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.